Leukemia

Article	Citations
Quantifying measurable residual disease correctly	2632
The 5th edition of the WHO classification of haematolymphoid tumors: comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH)	2379
MCL1 as a therapeutic vulnerability in Burkitt lymphoma	176
Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials: a SEER-Medicare analysis	154
CD36 cell surface expression as a surrogate marker to identify ABL/JAK-class kinase fusions in pediatric BCP-ALL	130
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis	112
Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core	102
Correction: Frequent HLA-DR loss on hematopoietic stem progenitor cells in patients with cyclosporine-dependent aplastic anemia carrying HLA-DR15	98
Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study	94
Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradication	91
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age	91
The potential of cell-free DNA to reveal the molecular profiles of Langerhans cell histiocytosis and Erdheim–Chester disease in adults	90
Rheumatoid arthritis and the risk of hematologic malignancies: a nationwide cohort study	86
Retraction Note: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide	83
Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies	81
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial	81
Mutant IL7R collaborates with MYC to induce T-cell acute lymphoblastic leukemia	79
Real life evaluation of AlphaMissense predictions in hematological malignancies	78
Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation	73
An MDM2 degrader for treatment of acute leukemias	72
The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH)	70
Characterisation and prognostic impact Of ZRSR2 mutations in myeloid neoplasms	70
Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)	69
Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms	63
Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial	63

Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia	63
Diverse mechanisms of leukemogenesis associated with PAX5 germline mutation	62
Nucleic acid therapeutics as differentiation agents for myeloid leukemias	62
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries	60
Real-time genomic characterization of pediatric acute leukemia using adaptive sampling	57
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial	57
Cohesin mutations in acute myeloid leukemia	56
Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche	56
Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia	55
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma	55
DDX41 coordinates RNA splicing and transcriptional elongation to prevent DNA replication stress in hematopoietic cells	53
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation	53
Clonal medicine targeting DNA damage response eradicates leukemia	53
Essential role of Dhx16-mediated ribosome assembly in maintenance of hematopoietic stem cells	52
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9	52
Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma	51
Invasive fungal diseases impact on outcome of childhood ALL – an analysis of the international trial AIEOP-BFM ALL 2009	51
Donor selection in T-cell-replete haploidentical donor peripheral blood stem cell transplantation	49
Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase	49
Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma	49
Oncogenic dependency on SWI/SNF chromatin remodeling factors in T-cell acute lymphoblastic leukemia	48
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression	48
A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy	48
PHF6 suppresses self-renewal of leukemic stem cells in AML	46
Measurable residual disease (MRD)-testing in haematological and solid cancers	46
Response to Pfirrmann et al.’s comment on How should we interpret conclusions of TKI-stopping studies	45
Znf687 recruits Brd4-Smrt complex to regulate gfi1aa during neutrophil development	45
Publisher Correction: Rolf Neth (October 6, 1926–March 17, 2020)	44
Correction to: Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors	44
Correction: Mitochondrial regulation of GPX4 inhibition–mediated ferroptosis in acute myeloid leukemia	43
Allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with t(16;21)(p11;q22)/FUS::ERG	43
miR-196b-Oct1/2 axis regulates DNMT3A-mutant AML pathogenesis	43
A bioinformatics perspective on molecular classification of diffuse large B-cell lymphoma	42
DNA demethylating agents for chemoprevention of oncovirus-associated leukemogenesis	42
Combining lenalidomide with erythropoiesis stimulating agents: a party of one	42
Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials	41
Hemolytic versus malproductive anemia in large granular lymphocytic leukemia	41
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia	40
Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia	40
STING is crucial for the survival of RUNX1::RUNX1T1 leukemia cells	40
Transient regulation of RNA methylation in human hematopoietic stem cells promotes their homing and engraftment	40
Impaired binding affinity of YTHDC1 with METTL3/METTL14 results in R-loop accumulation in myelodysplastic neoplasms with DDX41 mutation	39
Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia	39
CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL	37
Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia	37
Ppm1d truncating mutations promote the development of genotoxic stress-induced AML	37
RNAseqCNV: analysis of large-scale copy number variations from RNA-seq data	36
Sirolimus is effective for refractory/relapsed/intolerant acquired pure red cell aplasia: results of a prospective single-institutional trial	36
Central nervous system involvement in childhood acute lymphoblastic leukemia: challenges and solutions	36
CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia	35

METTL3 mediates chemoresistance by enhancing AML homing and engraftment via ITGA4	35
Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia	35
Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment – an intraindividual analysis by the German Study Group for MPN (GSG-MPN)	34
Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia	34
Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemia	34
Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL	33
PD-1 expression contributes to functional impairment of NK cells in patients with B-CLL	33
Validation and refinement of a RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia	33
CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study	33
Second versus first wave of COVID-19 in patients with MPN	33
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib	33
Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo	33
Germline PTPN13 mutations in patients with bone marrow failure and acute lymphoblastic leukemia	33
Whole-genome sequencing of myeloproliferative neoplasms revealed dynamic clonal changes in the fibrotic or leukemic transformation and novel FOXP1 mutations in the fibrotic transformation	32
New criteria for estimating numbers of CD34-positive cells in a graft needed for posttransplant bone marrow recovery	32
CLL cell-derived exosomes alter the immune and hematopoietic systems	32
Correction: Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks	32
Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study	32
Chromosome 9p trisomy increases stem cells clonogenic potential and fosters T-cell exhaustion in JAK2-mutant myeloproliferative neoplasms	32
A primary hierarchically organized patient-derived model enables in depth interrogation of stemness driven by the coding and non-coding genome	32
Emerging T-cell lymphomas after CAR T-cell therapy	31
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis	31
Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells	31
Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib	31
BRAFV600E promotes DC3/monocyte differentiation in human gene-engineered HSPCs and causes multisystem histiocytosis	30
Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-	30
Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms	30
How should we interpret conclusions of TKI-stopping studies	30
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients	30
Functions of the native NPM1 protein and its leukemic mutant	30
Insufficiency of FZR1 disturbs HSC quiescence by inhibiting ubiquitin-dependent degradation of RUNX1 in aplastic anemia	30
Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm	30
MYC, mitochondrial metabolism and O-GlcNAcylation converge to modulate the activity and subcellular localization of DNA and RNA demethylases	30
TP53 and CDKN2A alterations define a poor prognostic subgroup in patients with nodal T follicular helper cell lymphoma	29
The role of ASXL1, SRSF2, and EZH2 mutations in chromatin dysregulation of myelodysplastic neoplasia and acute myeloid leukemia	28
Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants	28
Improved CAR-T cell activity associated with increased mitochondrial function primed by galactose	28
Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia—a Grand Ouest Against Leukemia (GOAL) study	28
RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort	28
Targeting proteostasis in multiple myeloma through inhibition of LTK	28
The exon-junction complex helicase eIF4A3 holds therapeutic potential in acute myeloid leukemia	27
Mitochondrial regulation of GPX4 inhibition–mediated ferroptosis in acute myeloid leukemia	27
Correction to: Organ dysfunction, thrombotic events, and malignancies in patients with idiopathic multicentric Castleman disease: a population-level US health claims analysis	26
AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics	26
The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms	26
NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia	26
Correction: PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathways	26
Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia	26
Relationship among three common hematological premalignant conditions	26
T-cell diversity and exclusion of blood-derived T-cells in the tumor microenvironment of classical Hodgkin Lymphoma	26
Correction: Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment	26
Cre recombinase promotes leukemogenesis in the presence of both homozygous and heterozygous FLT3-ITD	26
Sulforaphane promotes natural killer cell-mediated anti-tumor immune responses partially via cGAS-STING pathway in classical Hodgkin lymphoma	25
Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia	25
Immunogenetics in hematopathology and hematology: why a common language is important	25
Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632)	25
What is radiation-induced acute myeloid leukaemia/can it be accurately identified?	25
Pre-diagnosis dietary patterns and risk of multiple myeloma in the NIH-AARP diet and health study	25
Refining histopathological growth pattern-based risk group discrimination in nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group	25
How fast does leukemia progress?	25
S1P-S1PR3-RAS promotes the progression of S1PR3hi TAL1+ T-cell acute lymphoblastic leukemia that can be effectively inhibited by an S1PR3 antagonist	25
Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma	24
Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia	24
Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?	24
Leukemogenesis occurs in a microenvironment enriched by extracellular microvesicles/exosomes: recent discoveries and questions to be answered	24
The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms	24
Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysis	24
EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma	23
A pro B cell population forms the apex of the leukemic hierarchy in Hoxa9/Meis1-dependent AML	23
The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia	23
Patterns of relapse in patients with multiple myeloma receiving chimeric antigen receptor T cell therapy: a multi-center analysis	23
Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies	23
A novel gene fusion RUNX1/ZNF423 promotes leukemic relapse of NUP98-rearranged AML	23
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer	23
Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis	23
Harnessing upregulated E-selectin while enhancing SDF-1α sensing redirects infused NK cells to the AML-perturbed bone marrow	23
Single-cell RNA sequencing of a new transgenic t(8;21) preleukemia mouse model reveals regulatory networks promoting leukemic transformation	23
Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children’s Oncology Group study	22
Inhibition of the m6A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia	22
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial	22

KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia	22
Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study	22
Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction	22
Characterization of immune exhaustion and suppression in the tumor microenvironment of splenic marginal zone lymphoma	22
MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis	22
KDM6B protects T-ALL cells from NOTCH1-induced oncogenic stress	22
Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period	21
A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses	21
Targeting ZDHHC21/FASN axis for the treatment of diffuse large B-cell lymphoma	21
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY	21
miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease	21
SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice	21
Elihu H. Estey, MD: leukemia expert, statistician, and gentle soul (July 15, 1946–October 8, 2021)	21
Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations	21
Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia	21
Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements	20
Challenges determining the best target duration of deep molecular response after which to attempt achieving therapy-free remission in chronic myeloid leukaemia	20
Profound sympathetic neuropathy in the bone marrow of patients with acute myeloid leukemia	20
Correction: Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway	20
LIN28B promotes differentiation of fully transformed AML cells but is dispensable for fetal leukemia suppression	20
The histone demethylase KDM5C functions as a tumor suppressor in AML by repression of bivalently marked immature genes	20
Recommendations for future extensions to the HGNC gene fusion nomenclature	20
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study	20
Impact of emerging ACA on survival in chronic myeloid leukemia (CML)	20
ADH5/ALDH2 dehydrogenases and DNA polymerase theta protect normal and malignant hematopoietic cells from formaldehyde challenge: therapeutic implications	20
Cerebrospinal fluid proteomics exerts predictive potential for immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR-T cell therapy	20
Survival with chronic myeloid leukaemia after failing milestones	20
NPM1-fusion proteins promote myeloid leukemogenesis through XPO1-dependent HOX activation	20
What do atomic bomb survivors teach us about therapy-free remission in people with chronic myeloid leukaemia?	19
Outcomes based on treatment setting in refractory acute myeloid leukemia and other high-grade myeloid malignancies	19
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) In	19
Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma	19
Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach	19
Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment	19
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms	19
Skin lesions, arthritis, chondritis, and cytopenias	19
Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients	19
Apoliprotein E-mediated ferroptosis controls cellular proliferation in chronic lymphocytic leukemia	19
Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms	19
Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis	19
Glucose uptake capacity of leukaemia cells in vitro correlates with response to induction therapy in acute myeloid leukaemia	19
Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia	19
Measurable residual disease in chronic lymphocytic leukemia. Where do we stand?	19
Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia	19
Association between CEP72 genotype and persistent neuropathy in survivors of childhood acute lymphoblastic leukemia	19
Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures	19
Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma	19
Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma	19
Updates of the ERIC recommendations on how to report the results from immunoglobulin heavy variable gene analysis in chronic lymphocytic leukemia	18
High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL	18
Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemia	18
Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia	18
Improved survival with younger HLA-matched unrelated donors versus older matched sibling donor HCT with PTCy-prophylaxis	18
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma	18
Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis	18
Spred1 deficit promotes treatment resistance and transformation of chronic phase CML	18
P4HA2 hydroxylates SUFU to regulate the paracrine Hedgehog signaling and promote B-cell lymphoma progression	18
Clinical phenotypes, molecular analysis, and outcomes of patients with Rosai-Dorfman disease	18
Overt and covert genetic causes of pediatric acute lymphoblastic leukemia	18
Acute myeloid leukemia: does sex matter?	17
GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma	17
A genome-wide association study identifies an African-specific locus on chromosome 21q22.12 associated with Burkitt lymphoma risk and survival	17
Correspondence to “A novel lncRNA SNHG29 regulates EP300-related histone acetylation modification and inhibits FLT3-ITD AML development”	17
Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition	17
Molecular mechanisms underlying transformation of large granular lymphocytic leukemia to high-grade T-cell lymphoma	17
Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance	17
Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic leukemia	17
Co-variates associated with outcomes of tyrosine kinase-inhibitor therapy in persons with chronic myeloid leukaemia initially presenting in accelerated phase	17
Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia	17
Prognostic impact of RUNX1 mutations and deletions in pediatric acute myeloid leukemia: results from the French ELAM02 study group	17
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia	17
Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells	17
The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)	17
RBC distribution width predicts thrombosis risk in polycythemia vera	16
Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations	16
Correction: Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia	16
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)	16
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community	16
PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia	16
Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis	16
How well do different chatbots respond to multiple myeloma treatment guidelines?	16
High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia	16
Intensive post-remission therapy does not decrease relapse after allotransplants for acute myeloid leukaemia in 1st remission and should not be given	16
Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working p	16
The protein deacetylase HDAC10 controls DNA replication in malignant lymphoid cells	16
MCL1 regulates AML cells metabolism via direct interaction with HK2. Metabolic signature at onset predicts overall survival in AMLs’ patients	16
Germline CHEK2 mutations in patients with myeloid neoplasms	16
The landscape of RNA-chromatin interaction reveals small non-coding RNAs as essential mediators of leukemia maintenance	16
Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis	16
Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation	16
DNA-TG and risk of sinusoidal obstruction syndrome in childhood acute lymphoblastic leukemia	16
A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure	16
Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection	16
Analysis of autophagy in DLBCL reveals subtype-specific differences and the preferential targeting of ULK1 inhibition in GCB-DLBCL provides a rationale as a new therapeutic approach	16
Ruxolitinib mediated paradoxical JAK2 hyperphosphorylation is due to the protection of activation loop tyrosines from phosphatases	16